Opiant Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
233 Wilshire Blvd, Suite 400, Santa Monica, CA
Fiscal year end
December 31
Former names
Lightlake Therapeutics Inc. (to 1/22/2016), Madrona Ventures, Inc. (to 10/9/2009)
Latest financial report
10-Q - Q3 2022 - Nov 14, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 836 % -11.8%
Debt-to-equity 62.6 % -9.57%
Return On Equity -97.2 % -2386%
Return On Assets -59.8 % -2480%
Operating Margin -141 % -2260%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.17M shares +9.48%
Common Stock, Shares, Outstanding 5.16M shares +11.8%
Common Stock, Value, Issued 5.17K USD +11.8%
Weighted Average Number of Shares Outstanding, Basic 5.14M shares +15.2%
Weighted Average Number of Shares Outstanding, Diluted 5.14M shares -15.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 22.3M USD -49.1%
Research and Development Expense 25.6M USD +54.2%
Selling and Marketing Expense 9.58M USD +138%
General and Administrative Expense 14.8M USD +19.8%
Operating Income (Loss) -31.5M USD -1199%
Nonoperating Income (Expense) -1.51M USD +14%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -33M USD -3085%
Income Tax Expense (Benefit) 65.3K USD
Net Income (Loss) Attributable to Parent -33.1M USD -2206%
Earnings Per Share, Basic -6.49 USD/shares -351%
Earnings Per Share, Diluted -6.37 USD/shares -445%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.4M USD +0.26%
Marketable Securities, Current 0 USD -100%
Accounts Receivable, after Allowance for Credit Loss, Current 41.1K USD -99.7%
Assets, Current 38.5M USD -43.2%
Property, Plant and Equipment, Net 418K USD +347%
Operating Lease, Right-of-Use Asset 2.74M USD +175%
Intangible Assets, Net (Excluding Goodwill) 10.6K USD -11.5%
Other Assets, Noncurrent 234K USD
Assets 42M USD -39.2%
Employee-related Liabilities, Current 1.82M USD +35.2%
Contract with Customer, Liability, Current 0 USD
Liabilities, Current 7.04M USD -4.24%
Operating Lease, Liability, Noncurrent 2.08M USD +191%
Liabilities 21.4M USD -20.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -248K USD -824%
Retained Earnings (Accumulated Deficit) -95.5M USD -53%
Stockholders' Equity Attributable to Parent 20.5M USD -51.2%
Liabilities and Equity 42M USD -39.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.1M USD -223%
Net Cash Provided by (Used in) Financing Activities 97.5K USD -83.2%
Net Cash Provided by (Used in) Investing Activities 12.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 5.16M shares +11.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.4M USD +0.26%
Interest Paid, Excluding Capitalized Interest, Operating Activities 415K USD +262%
Operating Lease, Liability 2.75M USD +174%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -33.3M USD -2108%
Lessee, Operating Lease, Liability, to be Paid 3.44M USD +176%
Operating Lease, Liability, Current 669K USD +133%
Lessee, Operating Lease, Liability, to be Paid, Year Two 737K USD +212%
Lessee, Operating Lease, Liability, to be Paid, Year One 709K USD +176%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 688K USD +180%
Lessee, Operating Lease, Liability, to be Paid, Year Three 780K USD +216%
Lessee, Operating Lease, Liability, to be Paid, Year Four 101K USD -63.4%
Share-based Payment Arrangement, Expense 800K USD +300%
Interest Expense 1.72M USD -2.37%